Search Results 371-380 of 9274 for Mediate

  1. Durvalumab+/- Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (Caspian) - Mayo Clinic

    No prior exposure to immune-mediated therapy excluding therapeutic anticancer vaccines. Exclusion Criteria: Any history of radiotherapy to the chest prior ...

  2. Pain Medicine Fellowship (Minnesota) - Curriculum

    ... mediated pain, head and facial pain, neuropathic pain, visceral pain, and myofascial pain. Most patients are seen as direct referrals from other Mayo Clinic ...

  3. A Study Comparing Tarlatamab, Durvalumab, Carboplatin, And Etoposide Versus Durvalumab, Carboplatin, And Etoposide In First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC) - Mayo Clinic

    * They will have no history of severe or life-threatening events to immune-mediated therapy. * History of arterial thrombosis (eg, stroke or transient ...

  4. A Study of SC‑004 in Subjects With Advanced Solid Tumors - Mayo Clinic

    Any prior history of immune-mediated pneumonitis, regardless of grade, based on NCI CTCAE v.4.03;; Any immune-mediated toxicity of Grade 3 or worse severity; ...

  5. Vascular Function in Breast Cancer Survivors - Mayo Clinic

    Obesity is independently associated with vascular dysfunction, a result of adipokine-mediated inflammation in obesity [6]. Vascular dysfunction is also ...

  6. Molecular Pharmacology & Experimental Therapeutics - Tracks - Ph.D. Program in Biomedical Science

    “Elucidation of MRAS-Mediated Noonan Syndrome,” Sherri Biendarra-Tiegs, Ph.D. (Mentor: Michael J. Ackerman, M.D., Ph.D.) “Investigating Seeding and ...

  7. Immune Dysfunction in Autoimmune Disease - Mayo Clinic

    Participation eligibility · Diagnosis of rheumatoid arthritis defined by ACR/EULAR criteria. · Diagnosis of immune-mediated disease affecting the joint, the lung, ...

  8. Chella S. David, Ph.D. - Mayo Clinic Faculty Profiles

    Role of HLA Class II Molecules in Immune Response to Bacterial Superantigens. Humans are much more sensitive to bacterial toxins than mouse and is mediated by ...

  9. Publications - Melanie C. Bois, M.D. - Mayo Clinic

    ... mediated rejection (AMR-H) in cardiac transplant endomyocardial biopsies. Cardiovasc Pathol. 2024 Sep-Oct; 72:107646 Epub 2024 Apr 26. View PubMed; Kim BM ...

  10. Publications - Andrea G. Kattah, M.D. - Mayo Clinic

    Kattah AG, Fervenza FC. Rituximab: emerging treatment strategies of immune-mediated glomerular disease. Expert Rev Clin Immunol. 2012 Jul; 8(5):413-21. View ...